Cardiol Therapeutics: From Chicago Spotlight to Market Survival – Why Investors Must Reevaluate
Cardiol Therapeutics: a biotech’s struggle to turn anti‑inflammatory research into real value, with low stock, negative P/E and a hopeful but uncertain regulatory path.
2 minutes to read
